EDITORIAL
The growing role of AI in breast cancer
The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes
Breast cancer research: lessons learnt from the past will shape the future
In her key lecture, the 2024 ESMO Breast Cancer Awardee Prof. Hope S. Rugo reflects on the current challenges in the field
Atezolizumab does not improve prognosis in early relapsing advanced triple-negative breast cancer
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it
OTHER NEWS
Fuzuloparib prolongs progression-free survival in HER2 negative metastatic breast cancer
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
Prolonged use of adjuvant imatinib shows promise in localised GIST
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
How much ‘green’ is cancer research?
Clinical trials have an impact on the environment, and novel approaches may help researchers reshape their activities toward a greater sustainability
Health as a human right, cancer care as a human priority
Universal health coverage in oncology is still not a reality, as a recent report shows
Use of ctDNA as a surrogate in early clinical drug development – nearing its end point?
Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
ROAD TO ESMO GASTROINTESTINAL CANCERS CONGRESS 2024
Extending the continuum of care for metastatic colorectal cancer
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
OPINIONS
Making personalised precision medicine a reality for early breast cancer
Nadia Harbeck
New insights into the evolutionary pattern of breast cancer
Tomomi Nishimura
Breast cancer: is the future of PARP inhibitors bright?
Carmen Criscitiello
#ESMOBreast24: Reasons to attend this top, international Congress for the breast cancer community
All videosOPINIONS
Making personalised precision medicine a reality for early breast cancer
Nadia Harbeck
New insights into the evolutionary pattern of breast cancer
Tomomi Nishimura
Breast cancer: is the future of PARP inhibitors bright?
Carmen Criscitiello